IRIX Nasdaq Electromedical & Electrotherapeutic Apparatus Financials FY2017βFY2026
Iridex Corp had $52.7M of revenue in fiscal 2026, up 8.2% on the year before. Over five years, revenue changed +7.7% a year on average.
Last close Β· Oct 23, 2026
$0.75
2.2%Hi! I read Iridex Corpβs latest annual report (fiscal 2026). Here is what stands out:
Good So-so Weak
Are sales growing?
+8.2%
Yes. Sales grew 8.2% last year.
Does it make a profit?
β8.4%
No. It lost money last year.
Does profit turn into cash?
β4.3%
No. It spent more cash than it brought in.
How healthy are the accounts?
4 / 8
Mixed. It passes 4 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Iridex Corp did it, and the next one. Share prices often move a lot on those days.
Next results
November 10, 2026
Tuesday Β· in 15 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 18, 2026 | Q2 '27 | After the market closes | 8-K β |
| May 19, 2026 | Q1 '27 | After the market closes | 8-K β |
| Jan 12, 2026 | Q4 '26 | Before the market opens | 8-K β |
| Nov 11, 2025 | Q3 '26 | Time not announced | 8-K β |
| Aug 12, 2025 | Q2 '26 | After the market closes | 8-K β |
| Apr 14, 2025 | Q1 '26 | After the market closes | 8-K β |
| Jan 14, 2025 | Q4 '25 | During market hours | 8-K β |
| Nov 12, 2024 | Q3 '25 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Iridex Corp had $52.7M of revenue in fiscal 2026, up 8.2% on the year before. Over five years, revenue changed +7.7% a year on average. Its operating margin was β4.9%, up 12.2Β pts: of every 100 in sales, about β5 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Iridex Corp lost $4.4M in fiscal 2026.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was β$2.3M in fiscal 2026, β4.3% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Iridex Corp can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $23.9M | $13.9M | $7.0M | $2.4M | $6.0M |
| Debt incl. finance leases | β | β | β | $2.7M | β |
| Debt / equity | β | β | β | 1.3x | β |
| Interest coverage | β | β | β | β56.9x | β44.3x |
| Current ratio | 3.3x | 2.9x | 2.1x | 1.4x | 1.9x |
| Quick ratio | 2.7x | 2.0x | 1.4x | 0.8x | 1.3x |
| Total assets | $48.7M | $42.3M | $34.4M | $29.1M | $29.2M |
| Total liabilities | $25.4M | $25.1M | $24.9M | $27.0M | $24.2M |
| Shareholders' equity | $23.3M | $17.2M | $9.5M | $2.1M | $4.9M |
| Net debt (β = net cash) | β | β | β | $0.3M | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Iridex Corp passes 4 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 8 | 4 / 8 | 4 / 8 | 4 / 8 | 4 / 8 | 2 / 8 | 2 / 8 | 2 / 8 | 4 / 8 |
| Accruals ratio | β24.0% | β20.7% | β6.7% | β2.4% | β9.9% | β35.1% | 4.3% | β7.4% | β5.1% | β8.0% |
| Altman Z'' | 8.26 | 3.11 | 1.92 | β0.59 | β2.59 | β0.25 | β2.23 | β6.28 | β10.10 | β8.01 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $46.2M | $41.6M | $42.6M | $43.4M | $36.3M | $53.9M | $57.0M | $51.9M | $48.7M | $52.7M |
| Gross profit | $20.8M | $15.5M | $17.5M | $17.9M | $15.6M | $22.8M | $25.4M | $21.8M | $19.5M | $19.2M |
| Research and development | $5.4M | $5.2M | $4.0M | $3.7M | $3.3M | $6.9M | $7.2M | $6.8M | $5.4M | $3.7M |
| Operating income | β$2.6M | β$12.9M | β$12.9M | β$9.0M | β$6.6M | β$7.5M | β$7.5M | β$10.0M | β$8.3M | β$2.6M |
| Interest expense | β | β | β | β | β | β | β | β | $0.1M | $0.1M |
| Pretax income | β$2.7M | β$13.0M | β$12.8M | β$8.8M | β$6.3M | β$5.2M | β$7.5M | β$9.5M | β$8.8M | β$4.4M |
| Income tax | $9.1M | β$0.1M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M |
| Net income | β$11.7M | β$12.9M | β$12.8M | β$8.8M | β$6.3M | β$5.2M | β$7.5M | β$9.6M | β$8.9M | β$4.4M |
| Diluted EPS | β$1.15 | β$1.11 | β$1.05 | β$0.64 | β$0.46 | β$0.34 | β$0.47 | β$0.59 | β$0.54 | β$0.26 |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B |
| Cash flow | ||||||||||
| Cash from operations | β$0.1M | β$3.6M | β$10.0M | β$7.9M | β$3.2M | $8.2M | β$9.5M | β$6.7M | β$7.3M | β$2.1M |
| Capital expenditure | $1.1M | $0.6M | $0.4M | $0.1M | $0.1M | $0.2M | $0.3M | $0.1M | $0.0M | $0.1M |
| Free cash flow | β$1.2M | β$4.1M | β$10.5M | β$8.0M | β$3.3M | $8.0M | β$9.8M | β$6.9M | β$7.3M | β$2.3M |
| Depreciation and amortization | $0.6M | $0.9M | $0.8M | $0.7M | $0.5M | $0.8M | $0.5M | $1.1M | $0.6M | $0.5M |
| Stock-based compensation | $1.8M | $1.9M | $1.8M | $1.7M | $1.1M | $1.6M | $1.6M | $1.7M | $1.2M | $0.8M |
| Acquisitions | β | β | β | β | β | $5.3M | $0.0M | β | β | β |
| Share buybacks | $0.1M | β | β | β | β | β | β | β | β | β |
| Dividends and buybacks | $0.1M | β | β | β | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $23.7M | $21.7M | $21.2M | $12.7M | $11.6M | $23.9M | $13.9M | $7.0M | $2.4M | $6.0M |
| Total debt | β | β | β | β | $1.2M | β | β | β | $2.7M | β |
| Current assets | $45.9M | $39.5M | $39.6M | $30.6M | $25.4M | $42.3M | $35.8M | $27.5M | $23.6M | $25.3M |
| Current liabilities | $8.2M | $10.4M | $10.5M | $9.8M | $8.7M | $12.6M | $12.5M | $13.0M | $16.6M | $13.2M |
| Inventory | $11.6M | $9.4M | $8.8M | $8.2M | $5.7M | $7.6M | $10.6M | $9.9M | $10.8M | $7.9M |
| Property and equipment, net | $1.5M | $1.4M | $1.2M | $0.7M | $0.4M | $0.4M | $0.5M | $0.4M | $0.1M | $0.1M |
| Goodwill | $0.5M | $0.5M | $0.5M | $0.5M | $0.5M | $1.0M | $1.0M | $1.0M | $1.0M | $1.0M |
| Intangible assets | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M | $2.2M | $2.0M | $1.6M | $1.3M | $1.0M |
| Total assets | $48.1M | $41.6M | $41.7M | $34.8M | $28.0M | $48.7M | $42.3M | $34.4M | $29.1M | $29.2M |
| Total liabilities | $9.0M | $11.1M | $11.7M | $12.1M | $10.6M | $25.4M | $25.1M | $24.9M | $27.0M | $24.2M |
| Preferred stock | β | β | β | β | β | $0.0M | $0.0M | $0.0M | $0.0M | β |
| Shareholders' equity | $39.2M | $30.5M | $30.0M | $22.7M | $17.4M | $23.3M | $17.2M | $9.5M | $2.1M | $4.9M |
| Margins | ||||||||||
| Gross margin | 45.1% | 37.3% | 41.0% | 41.3% | 42.8% | 42.4% | 44.5% | 42.0% | 40.1% | 36.5% |
| Operating margin | β5.6% | β31.0% | β30.2% | β20.7% | β18.1% | β14.0% | β13.2% | β19.3% | β17.1% | β4.9% |
| EBITDA margin | β4.2% | β28.9% | β28.3% | β19.1% | β16.7% | β12.5% | β12.4% | β17.2% | β15.9% | β3.9% |
| Net margin | β25.4% | β30.9% | β30.1% | β20.3% | β17.4% | β9.7% | β13.2% | β18.5% | β18.3% | β8.4% |
| FCF margin | β2.6% | β10.0% | β24.6% | β18.5% | β9.2% | 14.8% | β17.2% | β13.2% | β15.0% | β4.3% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β74.4% | β | β | β | β272.1% | β |
| Return on capital employed | β6.4% | β41.2% | β41.3% | β35.8% | β34.1% | β20.9% | β25.3% | β46.6% | β66.0% | β16.1% |
| Return on equity | β29.9% | β36.9% | β42.4% | β33.5% | β31.6% | β25.7% | β37.2% | β71.5% | β153.4% | β126.4% |
| Return on assets | β24.3% | β28.7% | β30.8% | β23.0% | β20.2% | β13.6% | β16.6% | β24.9% | β28.0% | β15.2% |
| Return on tangible equity | β30.4% | β43.1% | β43.7% | β39.9% | β37.8% | β26.0% | β52.8% | β138.4% | β | β149.2% |
| Growth | ||||||||||
| Revenue growth | β | β9.9% | 2.4% | 2.0% | β16.3% | 48.3% | 5.7% | β9.0% | β6.2% | 8.2% |
| FCF growth | β | β | β | β | β | β | β222.5% | β | β | β |
| Share count change | β | 13.6% | 5.6% | 12.4% | 1.0% | 11.4% | 3.4% | 1.2% | 1.9% | 3.0% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | 0.1x | β | β | β | 1.3x | β |
| Interest coverage | β | β | β | β | β | β | β | β | β56.9x | β44.3x |
| Current ratio | 5.6x | 3.8x | 3.8x | 3.1x | 2.9x | 3.3x | 2.9x | 2.1x | 1.4x | 1.9x |
| Quick ratio | 4.2x | 2.9x | 2.9x | 2.3x | 2.3x | 2.7x | 2.0x | 1.4x | 0.8x | 1.3x |
| Capital allocation | ||||||||||
| Capex / revenue | 2.3% | 1.4% | 1.0% | 0.3% | 0.3% | 0.4% | 0.5% | 0.2% | 0.0% | 0.3% |
| Stock comp / revenue | 3.9% | 4.6% | 4.2% | 3.9% | 3.1% | 3.0% | 2.8% | 3.2% | 2.6% | 1.5% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 4.0 | 4.0 | 4.0 | 4.0 | 2.0 | 2.0 | 2.0 | 4.0 |
| Altman Z'' | 8.3 | 3.1 | 1.9 | β0.6 | β2.6 | β0.2 | β2.2 | β6.3 | β10.1 | β8.0 |
| Accruals ratio | β24.0% | β20.7% | β6.7% | β2.4% | β9.9% | β35.1% | 4.3% | β7.4% | β5.1% | β8.0% |
Source: SEC EDGAR XBRL filings (CIK 0001006045). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
